ThermiGen owner Almirall said today that it sold its ThermiGen assets to Celling Biosciences for an undisclosed amount. The deal is expected to close on March 29, Barcelona-based Almirall said. Through the deal, Austin, Texas-based Celling Biosciences will take control of Thermi and its 94 Dallas-based employees as well as its more than 2,000 users, […]
FDA clears Thermi in “vaginal rejuvenation” product inquiry
Temp-controlled radiofrequency tech developer Thermi said this week that the FDA granted it a notice of completion following an inquiry on products used in “vaginal rejuvenation” procedures. Irving, Texas-based Thermi received a notice from the FDA on July 24 regarding specific claims about the company’s ThermiVa device. The ThermiVa is a non-ablative RF device cleared […]
Viveve settles IP suit against Thermigen
Viveve (NSDQ:VIVE) said this week it inked a settlement and licensing agreement with Thermigen and associated defendants to resolve a patent litigation claiming Thermigen improperly used Viveve intellectual property with its ThermiVa system. The resolution clears up all pending disputes between the companies, according to an SEC filing from Englewood, Colo.-based Viveve, and grants Thermigen a non-exclusive, […]
7 medtech stories we missed this week: May 26, 2017
From Merck’s new licensing agreement to surgical study data being touted, here are 7 medtech stories we missed this week but thought were still worth mentioning. 1. Merck inks exclusive licensing agreement for Alzheimer’s antibody Merck announced in a May 25 press release that it has entered an exclusive worldwide license agreement with Teijin Pharma. […]
